Home/Filings/4/0001209191-19-050361
4//SEC Filing

Bernard Gordon R 4

Accession 0001209191-19-050361

CIK 0001087294other

Filed

Sep 19, 8:00 PM ET

Accepted

Sep 20, 5:16 PM ET

Size

12.5 KB

Accession

0001209191-19-050361

Insider Transaction Report

Form 4
Period: 2019-09-13
Bernard Gordon R
Senior Vice President
Transactions
  • Sale

    Common Stock

    2019-09-17$4.91/sh711$3,49119,157 total
  • Sale

    Common Stock

    2019-09-18$4.95/sh2,987$14,78616,170 total
  • Sale

    Common Stock

    2019-09-19$5.21/sh4,000$20,84012,170 total
  • Sale

    Common Stock

    2019-09-13$5.11/sh3,117$15,92819,968 total
  • Sale

    Common Stock

    2019-09-16$5.05/sh100$50519,868 total
Footnotes (5)
  • [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person during March 2019. This plan was established due to the policy change at Vanderbilt Medical Center requiring that senior executives divest holdings in biopharmaceutical companies.
  • [F2]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $4.81, inclusive. The reporting person undertakes to provide to Cumberland Pharmaceuticals Inc., any security holder of Cumberland Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
  • [F3]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.16 to $5.08, inclusive.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.05 to $4.81, inclusive.
  • [F5]The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.35 to $5.13, inclusive.

Issuer

CUMBERLAND PHARMACEUTICALS INC

CIK 0001087294

Entity typeother

Related Parties

1
  • filerCIK 0001470015

Filing Metadata

Form type
4
Filed
Sep 19, 8:00 PM ET
Accepted
Sep 20, 5:16 PM ET
Size
12.5 KB